Inspire Medical ( (INSP) ) has released its Q1 earnings. Here is a breakdown of the information Inspire Medical presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Inspire Medical Systems, Inc. is a medical technology company specializing in innovative, minimally invasive solutions for obstructive sleep apnea, offering the first FDA-approved neurostimulation technology for this condition.
Inspire Medical Systems reported a robust first quarter for 2025, with a 23% increase in revenue year-over-year and earnings per share reaching $0.10. The company also achieved a significant milestone with over 100,000 patients receiving Inspire therapy.
Key financial highlights include a revenue of $201.3 million, with U.S. revenue growing by 24% while international revenue saw a slight decline. The company improved its operating loss by 90% compared to the previous year and reported a net income of $3.0 million, a significant turnaround from a net loss of $10.0 million in the same quarter last year. Inspire’s gross margin remained strong at 84.7%, and the company continues to invest in expanding its U.S. sales organization.
Looking ahead, Inspire Medical Systems maintains its full-year 2025 revenue guidance of $940 million to $955 million, reflecting a growth of 17% to 19% over the previous year. The company is also optimistic about the upcoming launch of its Inspire V system, which is expected to further drive growth and adoption in the U.S. market.